NCT01180764View on ClinicalTrials.gov

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

October 31, 2012

Conditions
Hypertriglyceridemia
Interventions
DRUG

Lovaza (Omega-3 acid ethyl esters)

1g capsules, 4 capsules po daily

DRUG

Placebo

Placebo matching active lovaza, 1 g capsules, 4 capsules po daily

Trial Locations (1)

84108

University of Utah, Salt Lake City

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Utah

OTHER

NCT01180764 - Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia | Biotech Hunter | Biotech Hunter